Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
Open Access
- 30 May 2017
- journal article
- case report
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 21, 171-175
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613Clinical Lung Cancer, 2017
- Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer TransformationJournal of Thoracic Oncology, 2017
- Tissue is the issue and tissue competition. Re‐biopsy for mutation T790: where and why?Clinical and Translational Medicine, 2017
- Osimertinib effective in EGFR T790M-positive lung cancerThe Lancet Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Mechanisms of resistance to EGFR tyrosine kinase inhibitorsActa Pharmaceutica Sinica B, 2015
- Treatment of non-small cell lung cancer (NSCLC)2013
- Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy2013
- Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyJournal of Cancer, 2013
- Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancerContemporary Oncology, 2012